Stephen McCulloh, MD
Family Medicine · Livingston, LANPI 1346563020
Payments from drug & device makers
Across 301 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$871
- Novo Nordisk$753
- Amgen$508
- Bayer$447
- Lilly USA, LLC$409
- Takeda Pharmaceuticals U.S.A., Inc.$372
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,620100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $871 |
| Novo Nordisk | 40 | $753 |
| Amgen | 36 | $508 |
| Bayer | 21 | $447 |
| Lilly USA, LLC | 23 | $409 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $372 |
| GSK | 20 | $337 |
| Novartis | 11 | $237 |
| AstraZeneca | 12 | $211 |
| Abbott | 6 | $206 |
| Boehringer Ingelheim | 11 | $189 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $183 |
| Merck | 9 | $145 |
| Pfizer | 6 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $90 |
| Amarin Pharma, Inc. | 6 | $90 |
| Dexcom, Inc. | 3 | $88 |
| Phathom Pharmaceuticals, Inc. | 4 | $70 |
| Exact Sciences | 3 | $56 |
| Astellas Pharma US Inc | 2 | $48 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,634 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 222 | $255,834 |
| OzempicSemaglutide | 129 | $147,665 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $107,343 |
| JardianceEmpagliflozin | 88 | $90,092 |
| EliquisApixaban | 75 | $71,140 |
| Repatha SureclickEvolocumab | 67 | $62,856 |
| JanuviaSitagliptin Phosphate | 76 | $60,663 |
| TrulicityDulaglutide | 40 | $43,549 |
| XareltoRivaroxaban | 51 | $38,810 |
| LinzessLinaclotide | 37 | $35,389 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $30,732 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $30,065 |
| VascepaIcosapent Ethyl | 32 | $22,049 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $17,030 |
| MyrbetriqMirabegron | 16 | $15,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $409 | $299,383262 claims |
| Novo NordiskOzempic | $753 | $147,665129 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $337 | $115,037128 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $189 | $107,941112 claims |
| MerckJanuvia, Janumet | $145 | $75,01889 claims |
| PfizerEliquis, Premarin | $118 | $73,47690 claims |
| AbbVieLinzess, Synthroid | $871 | $40,653119 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $35 | $30,73227 claims |
| AstraZenecaFarxiga, Symbicort | $211 | $20,96446 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $15,08416 claims |
| NovartisEntresto | $237 | $8,78813 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $21 | $2,304269 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Livingston
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.